Objective. Obesity is associated with an increased risk of developing osteoarthritis (OA), which is postulated to be secondary to adipose tissue-dependent inflammation. Periarticular adipose tissue depots are present in synovial joints, but the association of this tissue with OA has not been extensively explored. The aim of this study was to investigate differences in local adipose tissue depots in knees with OA and characterize the changes related to class II and class III obesity in patients with end-stage knee OA.
Methods. Synovium and the infrapatellar fat pad (IPFP) were collected during total knee replacement from 69 patients with end-stage OA. Histologic changes, changes in gene and protein expression of adiponectin, peroxisome proliferator-activated receptor g (PPARg), and Toll-like receptor 4 (TLR-4), and immune cell infiltration into the adipose tissue were investigated.
Results. IPFP and synovium adipose tissue depots differed significantly and were influenced by the patient's body mass index. Compared to adipocytes from the IPFP and synovium of lean patients, adipocytes from the IPFP of obese patients were significantly larger and the synovium of obese patients displayed marked fibrosis, increased macrophage infiltration, and higher levels of TLR4 gene expression. The adipose-related markers PPARg in the IPFP and adiponectin and PPARg in the synovium were expressed at lower levels in obese patients compared to lean patients. Furthermore, there were increased numbers of CD451 hematopoietic cells, CD451CD141 total macrophages, and CD141CD2061 M2-type macrophages in both the IPFP and synovial tissue of obese patients.
Conclusion. These differences suggest that IPFP and synovium may contain 2 different white adipose tissue depots and support the theory of inflammation-induced OA in patients with class II or III obesity. These findings warrant further investigation as a potentially reversible, or at least suppressible, cause of OA in obese patients.
The prevalence of obesity (defined as a body mass index [BMI] of $30 kg/m 2 ) has significantly increased within developed societies over the last decade. It has been estimated that more than 50% of adults in the US will be obese by 2030 (1) . Obesity, characterized by an excess of white adipose tissue due to an imbalance between calories consumed and calories expended, is associated with an increased risk of a number of diseases, including type 2 diabetes mellitus (DM), atherosclerosis (2) , and some types of cancer (3) . There is also a recognized association between obesity and osteoarthritis (OA) (4) , with obese individuals having a higher risk of developing OA in both the weight-bearing and non-weight-bearing joints.
Several mechanisms by which obesity may initiate or accelerate the progression of OA have been postulated. Biomechanical factors are likely to be important, since the weight-bearing joints are overloaded. However, the increased incidence of OA in non-weight-bearing joints indicates that other factors are also involved. It has been postulated that venous outlet obstruction in the subchondral bone might impair nutrient supply, making articular cartilage more susceptible to damage (5) . It is now becoming clear, however, that adipose tissue may create a systemic inflammatory milieu via the release of various cytokines and adipokines, which have the potential to damage articular cartilage directly (6) . Furthermore, increasing BMI is correlated with a higher content of free glycosaminoglycans in synovial fluid (7) , and both hypercholesterolemia and hypertriglyceridemia have been hypothesized to interfere with cartilage metabolism (8) .
White adipose tissue depots are predominantly present in subcutaneous sites (as subcutaneous adipose tissue [SAT]) or within the abdomen (as omental/visceral adipose tissue [VAT] ). In a healthy subject of normal weight, the majority of adipose tissue (up to 80%) is represented by SAT, and only 10-20% is represented by VAT. These depots differ in a number of features, such as adipocyte size, blood vessel density, and immune cell content (9, 10) . Adiponectin and peroxisome proliferator-activated receptor g (PPARg) are 2 important adipose tissue-related proteins. Adiponectin is a secretory protein that is postulated to have antiatherogenic and antiinflammatory properties (11) . PPARg is a nuclear receptor crucial for the differentiation of mesenchymal stem cells into mature adipocytes and is important in fatty acids and glucose metabolism.
Adipose tissue in healthy adults is dynamic, and its size and function may change depending on the level of incoming energy. Extracellular matrix (ECM) remodeling is essential to allow rapid adipose tissue responses to a nutrient deficiency or surplus. As such, there is constant matrix remodeling, with a balance between ECM production and ECM degradation. In obese individuals, hypertrophic adipocytes, which are unable to store additional triglycerides, start a process of lipolysis with associated tissue fibrosis (12) . These events lead to enhanced free fatty acid release. These free fatty acids may accumulate in other tissues, such as the liver, skeletal muscle, or joints, with consequent organ lipotoxicity (13, 14) .
Impaired adipocyte function in fat depots, in turn, leads to adipocyte necrosis, which triggers an influx of proinflammatory cells, including hematopoietic cells such as macrophages, mast cells, and subtypes of T cells (15) . Significantly, up to 30% of up-regulated genes in adipose tissue in obese individuals are related to macrophage function (16) . Increased levels of circulating saturated fatty acids, which are potent agonists of Toll-like receptors (TLRs) including TLR-2 and TLR-4, may also contribute to the production of a range of proinflammatory and profibrotic mediators recognized as being potential targets in the pathogenesis of OA (17) .
In synovial joints, adipose tissue is present in the subsynoviocyte intimal layer and in periarticular depots such as the infrapatellar fat pad (IPFP) of the knee joint. The physiologic role of these fat deposits and their origin are not well described. It has been suggested that fat deposits in the IPFP are similar in type to those in the SAT (18) due to the fibrous tissue surrounding adipocytes, whereas others support the notion that fat deposits in the IPFP are similar to those in the VAT (19) .
The aim of this study was to ascertain whether there are differences in the adipose tissue depots in the knee joints between obese and nonobese patients with end-stage knee OA. Additionally, we analyzed differences in the characteristics of the SAT and VAT and their potential to act as sites of local proinflammatory mediator production, a process that might contribute to the progression of OA.
PATIENTS AND METHODS
Sample collection. Ethics approval for the study was granted by the Lothian Research Ethics Committee and UK National Health Service Lothian Research and Development Management, which provided consent for the use of surgical discard tissue for this study. The tissue was obtained from patients (n 5 69) during primary total knee replacement surgery for knee OA. Patients were divided into a lean group (with a BMI of ,25 kg/m 2 ) and an obese group (patients with class II or class III obesity, with a BMI of $35 kg/m 2 ). The analyzed samples were isolated by the same surgeon (RB) with the same incision technique of harvesting synovial punch biopsy specimens from the suprapatellar synovial region and from the IPFP in the infrapatellar region. The synovial membrane was not separated from the adipose tissue.
Hematoxylin and eosin (H&E)-stained sections of knee joint tissue from each patient were analyzed; samples with increased synovial membrane inflammation were not analyzed in this study. In general, samples from OA patients had no more than 10-15% of total synovial membrane per whole-tissue biopsy sample. Representative results of histologic assessments are presented in Supplementary Figure 1 Histologic assessment, measurement of adipocyte area, and tissue staining with picrosirius red S. Tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 4-mm sections. The sections were deparaffinized, rehydrated, and stained with H&E or picrosirius red S. Images of 10 different regions (representing 50-150 adipocytes) in each sample (n 5 12 samples per group) were obtained at 20 3 magnification (for adipocyte size measurement) and 60 3 magnification (for picrosirius red S staining) on a Nikon Eclipse E800 microscope. Adipocyte size was then assessed by measuring the longest diameter (designated a) and the shortest diameter (designated b) for the area of an ellipse to calculate the area of the cell (designated A), using the following mathematical formula:
For quantification of fibrosis, images of picrosirius red Sstained sections were converted into an 8-bit image with the exclusion of the background, and the percentage area of fibrosis was calculated. For measurements of the adipocyte size and area of fibrosis, ImageJ software was used.
Immunohistochemical analyses. Immunohistochemical analyses were performed by incubating the tissue sections (n 5 10 samples per group) with the primary antibody (antihuman CD45 and anti-human CD206 antibodies [R&D Systems], and anti-human TLR4 antibodies [Bioss]) followed by a secondary antibody conjugated with horseradish peroxidase. The chromogenic substrate 3,3 0 -diaminobenzidine was used to develop the color. Counterstaining was performed with Harris' hematoxylin.
Tissue explant cultures and enzyme-linked immunosorbent assays (ELISAs). Tissue sections (n 5 5 samples per group) were cut into 1-3-mm 3 fragments, weighed, and cultured for 24 hours in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum and penicillin/ streptomycin. Explants were then cultivated (in duplicate) for 3 days in serum-free IMDM with penicillin/streptomycin. Thereafter, supernatants were collected and total adiponectin levels in the medium were assessed using an Adiponectin/Arcp30 Quantikine ELISA kit (R&D Systems). This kit allowed analysis of total adiponectin. The concentration of the protein produced was adjusted for the weight (in mg) of the wet tissue explant.
Western blotting. Tissue samples (n 5 7 samples per group) were snap-frozen in liquid nitrogen and homogenized. Protein concentrations were measured using a Bradford assay (Bio-Rad). In total, 25 mg of protein from each sample was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a PVDF membrane (Immobilon-FL) using a Bio-Rad Wet Transfer system. Blots were blocked by Odyssey Blocking buffer ( RNA isolation, complementary DNA (cDNA) synthesis, and real-time quantitative polymerase chain reaction (qPCR) analysis. RNA from IPFP and synovium samples (n 5 7 samples per group) was obtained using a combined QIAzol and Qiagen Mini RNA isolation kit technique. Stability of the RNA was established by gel electrophoresis, and 2 bands (28S RNA and 18S RNA) were detected. RNA purity was assessed by NanoDrop absorbance measurement with 260 nm/ 280 nm and 260 nm/230 nm absorbance ratios of .1.9. One microgram of RNA was treated with DNAse I (Invitrogen) and reverse transcribed using iSCRIPT (Bio-Rad) in accordance with the instructions of the suppliers. Real-time PCR was conducted on a LightCycler 96 (Roche). Ten nanograms of cDNA was analyzed. The primer concentration was 10 mM.
The reactions were performed in triplicate for each analyzed gene. Reactions using SYBR Green chemistry were also subjected to melting curve analysis. The amplification curves and efficiency of amplification of each gene were validated, and the efficiency values ranged from 95% to 105%. Values for target gene expression were normalized to those of the b 2 -microglobulin (B2M) reference gene. Relative messenger RNA (mRNA) expression was assessed using the 2 2DDCt method, with the lowest C t value serving as a calibrator (according to the method described by Schmittgen and Livak [20] ). In order to analyze the fold change in mRNA levels, values in the samples from lean patients were used as the reference level, being set at 1.0. The primer sequences used for assessment of gene expression were as follows: for ADIPOQ, forward GCA-TTC-AGT-GTG-GGA-TTG-GA and reverse TAA-AGC-GAA-TGG-GCA-TGT-TG (product size 80 kb); for PPARG, forward GCT-GTG-CAG-GAG-ATC-ACA-GA and reverse GGG-CTC-CAT-AAA-GTC-ACC-AA (product size 225 kb); for TLR4, forward AGC-TGT-ACC-GCC-TTC-TCA-GC and reverse CCT-GCC-AAT-TGC-ATC-CTG-TA (product size 152 kb); and for B2M, forward TGT-GCT-CGC-GCT-ACT-CTC-TC and reverse CCA-TTC-TCT-GCT-GGA-TGA-CG (product size 90 kb).
Flow cytometry. The stromovascular fraction from each tissue explant was obtained as follows. First, 1-3 gm of tissue was intensively washed with sterile PBS and minced into 1-2-mm 3 pieces, and then incubated for 1.5 hours at 378C in 2 mg/ml of type I and type II collagenases in 0.5% bovine serum albumin in Hanks' balanced salt solution with Ca 21 and Mg
21
. The cell fraction was filtered and lysed using Red Cell Lysis buffer (Millipore). Cells were then incubated in the dark for 30 minutes at 48C with anti-human CD45, anti-human CD14, and anti-human CD206 antibodies or isotype control antibodies (each at 1:100 dilution; ImmunoTool) and TLR4 antibodies (1:100 dilution; Statistical analysis. All statistical analyses were performed using GraphPad Prism software (version 6.0). The MannWhitney U test and Wilcoxon's matched pairs test were used to compare linear variables between groups, and Spearman's rho correlation was used to assess the association between nonparametric linear variables. A Mann-Whitney U test was performed for comparison of linear variables between groups (lean versus obese), and a Wilcoxon's matched pairs analysis was used to assess differences in linear variables between anatomic sites in the same group (IPFP versus synovium from the same donor). P values less than 0.05 were considered significant.
RESULTS
Association of obesity with changes in adipocyte size and fibrosis in knee joint fat depots. Histomorphometric analyses of the knee joint tissue demonstrated differences in adipocyte size and in the extent of fibrosis in knee joint fat depots between lean patients and obese patients (Figures 1A-D) (Figures 1A-C) . Furthermore, in the synovium, there was no significant difference between lean and obese patients in the median size of adipocytes (P 5 0.17), whereas in the IPFP, the median adipocyte size was significantly higher in obese patients compared to lean patients (P , 0.0001).
Analysis of pericellular fibrosis showed that the percentage area of fibrosis in the synovial tissue did not differ from that in the IPFP in knee joint samples from lean individuals ( Figure 1D ). Similarly, there was no difference in pericellular fibrosis seen between the IPFP and synovium of obese individuals. However, there was a significantly greater area of matrix deposition in the synovial adipose tissue of obese individuals (mean 6 SD 24.66 6 5.62%) compared to that of lean individuals (14.44 6 5.21%) (P , 0.005), whereas there was no significant difference in the area of matrix deposition in the IPFP (20.91 6 8.1% in obese patients versus 16.89 6 3.35% in lean patients). The mean area of adipocyte fibrosis was normalized to the median adipocyte size in each patient, to adjust for differences in adipocyte size.
Association of obesity with changes in adipose tissue-related gene and protein expression in knee joint fat depots. Real-time qPCR and Western blot analyses showed differential expression of adipose tissue-related genes and proteins in the synovium and IPFP of lean and obese individuals (Table 1 and Figures 2A-D) .
The expression levels of the ADIPOQ gene and adiponectin protein were not different in paired synovium and IPFP samples from lean patients, whereas in obese patients, their levels were significantly lower in the synovium compared to the IPFP (P 5 0.02 in qRT-PCR, P 5 0.04 in ELISA, and P 5 0.03 in Western blotting). Furthermore, synovium from lean patients expressed significantly higher levels of the ADIPOQ gene and adiponectin protein compared to synovium from obese subjects (P 5 0.04 in qRT-PCR, P 5 0.03 in ELISA, and P 5 0.004 in Western blotting), but there was no such difference between lean and obese patients in the IPFP (Table 1 and Figures 2A and C) .
Analysis of the expression of the PPARG gene and PPARg protein showed significantly lower expression levels in the synovium than in the IPFP in lean patients (P 5 0.02 in qRT-PCR and P 5 0.01 in Western blotting), but this difference between the synovium and the IPFP was not seen in obese patients. PPARg was also expressed at a significantly lower level in obese patients as compared to lean patients, both in the IPFP (P 5 0.02 in qRT-PCR and P 5 0.03 in Western blotting) and in the synovium (P 5 0.04 in qRT-PCR and P 5 0.03 in Western blotting) ( Table 1 and Figures 2B and D) .
Increased numbers of CD451 hematopoietic cells and macrophage content in the knee joint synovium and IPFP with obesity. Immunohistochemical and flow cytometric analyses of samples from lean individuals showed that the number of CD451 hematopoietic cells was significantly greater in the synovial adipose tissue than in the IPFP (mean 6 SD 18.7 6 6.9% versus 15.02 6 6.7%; P 5 0.03) ( Figures 3A and B) . In obese patients, the number of CD451 hematopoietic cells was elevated, as compared to that in lean patients, in both the IPFP (19.4 6 3.4%) and the synovium (26.6 6 8.7%) (P 5 0.04 for the IPFP, P 0.004 for the synovium). However, there was no difference in the number of CD451 hematopoietic cells between the IPFP and synovium of obese patients. Cell profiling by flow cytometry showed that the frequency of CD451CD141 total macrophages (mean 6 SD 8.2 6 3.5% in the IPFP, 8.84 6 2.15% in the synovium) and the frequency of CD141CD2061 M2-type macrophages (6.8 6 2.2% in the IPFP, 5.7 6 1.6% in the synovium) was not different between the synovium and IPFP of lean individuals (Figures 4A-C) . However, in obese individuals, the percentage of CD451CD141 total macrophages (10.6 6 4.1% in the IPFP, 12.5 6 2.8% in the synovium) and percentage of CD141CD2061 M2-type macrophages (8.9 6 3.2% in the IPFP, 9.5 6 2.6% in the synovium) were higher than that in lean individuals, both in the IPFP (P 5 0.02) and in the synovium (P 5 0.0001). The percentages of CD451 CD141 total macrophages and CD141CD2061 M2-type macrophages correlated significantly with the BMI score, as summarized in Figures 4A and B .
Increased TLR4 expression in the synovium of obese patients, and correlation with BMI. Real-time PCR analysis showed that TLR4 gene expression was not different between the synovium and IPFP of lean individuals (Table 1 ). There was a significantly higher expression of TLR4 in the synovium of obese patients compared to the synovium of lean patients (P 5 0.03). However, no difference in TLR4 expression was seen in the IPFP between lean and obese patients or between the IPFP and synovium of obese patients.
Flow cytometric analysis showed that the percentage of TLR41 cells did not differ between the synovium and the IPFP of lean patients (mean 6 SD 4.7 6 2.3% and 5.5 6 4.7%, respectively), but was significantly higher in the synovium of obese patients (9.6 6 3.7%) compared to the synovium of lean patients (P 5 0.009) (Figures 5A and  D) . The percentage of TLR41 cells in the synovium correlated with the BMI score ( Figure 5C ). There was no significant difference in the percentage of TLR41 cells in the IPFP between lean patients and obese patients (mean 6 SD 5.54 6 4.73% versus 9.0 6 3.81%), and there was no correlation of the percentage of TLR41 cells in the IPFP with BMI (Figures 5B and D) .
DISCUSSION
Obesity is a strong risk factor for the development of OA. The association of OA with obesity in both the loadbearing and non-load-bearing joints suggests that excessive or abnormal loading of the joints does not explain this relationship entirely. As such, an hypothesis suggesting that systemic/metabolic factors may play a role supports the notion that metabolic factors related to obesity act directly or indirectly on chondrocytes, leading to the increased risk of developing OA (21) . In the current study, we assessed whether there were any differences in the intraarticular fat deposits within the knee joint (namely, the synovium and the IPFP) of lean and obese individuals undergoing arthroplasty, which may indicate a local, in addition to a systemic, contribution to the development and progression of OA. We found that in lean individuals, the adipocytes were larger in the synovial adipose tissue than in the IPFP. Furthermore, there was no difference in the extent of pericellular fibrosis or in the levels of adiponectin, but expression of PPARg was significantly lower in the synovium compared to the IPFP of these patients.
A significantly higher content of CD451 hematopoietic cells was identified in the synovium compared to the IPFP, but no differences in macrophage numbers (characterized by the expression of CD451CD141 and CD141CD2061 cells) and no differences in the expression of TLR41 cells were seen in the fat deposits in lean individuals. In comparison, in obese patients, the size of adipocytes was larger in the IPFP than in the synovium, and pericellular fibrosis was greater in the synovial fat. In the synovium compared to the IPFP of obese patients with end-stage knee OA, the expression levels of adiponectin and PPARg were lower, whereas the expression of TLR4 was higher. In both the IPFP and synovium of obese patients, there was a significantly higher content of CD451 hematopoietic cells, CD451CD141 total macrophages, and CD141CD2061 M2-type macrophages, as compared to the IPFP and synovium of lean subjects.
In a previous study, immunohistochemical and flow cytometric analyses identified the presence of CD86 (M1-type marker) and CD206 (M2-type marker) in the IPFP, but did not find an influence of BMI on the numbers of these cells (22) . A recent study also demonstrated no differences in immune cell populations between paired IPFP and synovium samples; however, those authors investigated individuals with a mean BMI of 28.9 kg/m 2 (BMI range no more than 32 kg/m 2 ), and this may explain the contrasting results in comparison to those of the current study (23) .
Studies of fat deposits in obesity indicate that, with weight gain, adipocytes in the SAT increase in size significantly more than those in the VAT (9) . Results of the current study demonstrated that in obese patients, the size of adipocytes in the IPFP was significantly increased, whereas there was no change in the size of adipocytes in the synovium.
Fibrosis, a hallmark of metabolically dysfunctional white adipose tissue with resident adipocytes being surrounded by a network of ECM, is a typical feature of the visceral fat in obese patients (24) . Results of the current study, which demonstrated an increase in adipocyte size in the IPFP and augmented pericellular fibrosis in the synovial fat, support the theory that synovial and IPFP adipose tissue depots may each represent a different subtype of white adipose tissue. The synovial adipose tissue demonstrated characteristics akin to those of the VAT, whereas the characteristics of the IPFP were more in keeping with those of the SAT. Conversely, findings reported by other investigators have suggested a profibrotic role of the IPFP, which is independent of the BMI of the patient (25) . The extent of fibrosis and the deposition of collagen could have been quantified further in this study with the use of picrosirius red staining accompanied by polarized light to evaluate birefringence.
Adiponectin has been postulated to be both procatabolic (26, 27) and proanabolic (28) in OA. As such the influence of adiponectin on the OA pathogenetic pathway is not clear. The adiponectin concentration has been reported to be elevated in the serum of OA patients compared to healthy individuals (29) ; however, the levels of adiponectin in the synovial fluid are significantly lower than those in the peripheral blood of OA patients (30) . However, adiponectin levels in synovial fluid have been shown to correlate with proteoglycan catabolism (31) . The IPFP has been shown to produce more adiponectin than that produced by subcutaneous depot fat from the same donor (6, 32) , consistent with the observation of differential expression and production of adiponectin by the IPFP and the synovium in the current study. However, a negative correlation between adiponectin expression by the IPFP and the BMI of OA patients was not observed in the current study, as has been suggested by other authors (33) .
Differential expression of adiponectin has also been reported in various kinds of adipose tissue depots. SAT produces more adiponectin than VAT (34, 35) , and during weight gain, a significant down-regulation of adiponectin production in VAT, but not in SAT, has been reported (31) . We observed a decrease in adiponectin gene expression and protein production ex vivo by the synovium, but not the IPFP, of obese individuals. Although, in the present study, synovial membrane was not dissected from the adjacent adipose tissue, we hypothesize that the results obtained may indicate a difference in the origin of the 2 fatty tissue depots analyzed.
PPARg is a ligand-activated transcription factor that plays a key role in lipid homeostasis. Our data indicate that PPARg expression was significantly lower in both the IPFP and synovium of obese patients. Such changes are likely to have a proinflammatory/procatabolic effect in the joint, as PPARg activation in adipose tissue is associated with beneficial effects on the expression and secretion of a range of factors, including adiponectin by adipocytes and suppression of production of inflammatory mediators such as resistin, interleukin-6, and tumor necrosis factor by macrophages (36) . Notably, mice with cartilage-specific knockout of PPARg spontaneously develop OA (37), indicating a role for this transcription factor in the regulation of chondrocyte function, including inhibition of procatabolic pathways through support of autophagy (38) . PPARg agonists have potent antiinflammatory and anticatabolic activity when applied to articular chondrocytes and synovial fibroblasts (39) , and have been shown to have some degree of efficacy in instability-induced OA models in guinea pigs and dogs (40, 41) . Although the effects of these agents have not yet been shown in human studies, the lower expression of PPARg in tissue samples from the knee joints of obese patients indicates that targeted therapy for this subgroup of OA patients might be beneficial.
Leukocyte numbers increase with obesity, both in the circulation and in local adipose tissue depots, and are correlated with such proinflammatory diseases as type 2 DM (42) and liver steatosis (43) . Our flow cytometry and immunohistochemistry data indicate that the frequency of hematopoietic cells was significantly higher in the synovium than in the IPFP from lean patients with OA, with a further increase in the number of CD451 cells being seen in those with obesity, suggesting a more proinflammatory profile of both tissues. The main hematopoietic cells present in adipose tissue are macrophages, which are postulated to play an important role in obesity-related exacerbation of inflammation and organ fibrosis (44) . In the current study, we observed, for the first time, an increased frequency of CD141CD2061 M2-type macrophages in both knee joint synovial deposits and IPFP deposits from obese patients with OA, which correlated significantly with the patients' BMI. CD206 is considered to be an antiinflammatory macrophage marker. However, M2-type macrophages also play a role in profibrotic processes during wound healing and are an important source of the profibrotic factor transforming growth factor b (TGFb) (45) . This is a limitation of the current study and could be a very interesting future goal for further investigation, to determine the expression of TGFb in fatty tissue deposits in obesity-driven OA.
The expression levels of TLR4 and the number of TLR41 cells were significantly increased in the knee joint synovium from obese patients compared to lean patients in the current study. In keeping with this, the findings from our immunohistochemical analyses of TLR4 gene expression indicated that TLR4 was expressed at a significantly higher level in the synovial adipose tissue of obese patients compared to lean patients. In humans, expression of TLR4 is up-regulated in the VAT, but not in the SAT, from obese patients (46) , consistent with our premise that synovial fat deposits in the knee have characteristics of VAT. TLR-4 plays a crucial role the accumulation of macrophages in adipose tissue of obese patients (47) . TLR-4 ligands activate fibroblasts and promote their differentiation into collagen-producing cells (48) . Moreover, in adipose tissue, it is proposed that interactions between adipocytes and macrophages through TLR-4/myeloid differentiation protein 2 will aggravate adipose tissue inflammation (49) , and therefore possibly by such mechanisms, the progression of OA could be potentiated.
Our analysis of end-stage knee OA, the exclusion of patients with a BMI of between 30 and 35 kg/m 2 , and no separation of synovial membrane from adipose tissue are potential limitations of this study. However, recent studies and observations suggest that BMI is not a perfect index. People classified as obese with a BMI of 30 kg/m 2 have been shown to have the same health profile, or even a better health profile, than that of individuals of normal weight (50) . A further limitation was the effect of comorbidities, such as type 2 DM, which, given the number of patients and subgroups, was not possible to evaluate fully in the current study.
Thus, the findings of this study show that there are significant differences between synovial and IPFP adipose tissue in patients undergoing joint arthroplasty for knee OA, which supports the theory that synovial fat has characteristics of VAT, while the IPFP is more akin to SAT. Obesity is associated with changes in these fat depots, with synovial fat, in particular, showing changes typical of VAT, which is likely to be associated with a proinflammatory and catabolic phenotype. Nevertheless, there is an increased number of CD451 hematopoietic cells and CD451CD141 and CD141CD2061 macrophages in both adipose tissue depots in obese patients, which supports the idea that, in addition to biomechanical factors, local inflammation-produced mediators probably contribute to the development of OA in obese individuals. Targeting of this adipose tissue-dependent inflammation by novel therapies, such as PPARg agonists, may have a benefit and delay the progression of OA in obese patients.
